SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rises amid concerns that Middle East tensions and attacks on shipping and energy infrastructure could disrupt supply. Traders are divided between expecting further gains from the supply-risk premium and betting that diplomacy, easing tensions, or an overextended rally could pull prices back.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI infrastructure and neocloud stocks, fueled by worries about financing costs, debt, and whether AI buildout spending will earn adequate returns. Traders are split on whether the oversold rebound signals stabilization or is a bull trap, with some arguing Nebius is better positioned than more debt-heavy peers.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small caps are under pressure amid hotter inflation readings and concerns that interest rates may stay higher, with traders noting the Russell 2000s sensitivity to borrowing costs and its technical weakness. Some see oversold conditions and sector rotation as support for a rebound, while others expect further downside if key support fails.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules have raised the possibility that Strategy could be removed from major benchmarks, fueling concerns about forced passive-fund selling and adding pressure amid Bitcoin volatility. Traders are split between expecting further downside and buying the dip, with dilution and the companys preferred-stock buyback strategy also drawing criticism; removal has not been confirmed.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops reminder that its shareholder warrants are nearing expiration is driving attention, with traders focused on whether the shares can rise above the exercise price before the deadline. Bears expect the warrants to expire worthless, avoiding dilution, while bulls speculate that Ryan Cohen may take action to lift the stock or extend the deadline.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a sharp semiconductor selloff, as traders debate whether AI infrastructure spending can generate sufficient returns and whether debt risks at companies such as CoreWeave signal broader trouble. Bears see more downside if capex and financing concerns persist, while bulls view the pullback as overdone and expect upcoming earnings and guidance to reinforce AI-chip demand.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being linked to concerns about Trumps political standing ahead of the midterms and doubts about the companys business prospects, including Truth Social engagement. The discussion is overwhelmingly bearish, though some traders see a potential bounce or short squeeze.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a broader semiconductor and AI-stock selloff, with traders questioning whether AI infrastructure spending can be financed and generate sufficient returns; some also say CEO Hock Tans casino remarks hurt sentiment. The discussion is split between bears focused on AVGOs weak performance versus chip peers and dip-buyers citing AI demand and the NTT DOCOMO VMware agreement.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

KFCs planned switch from Pepsi to Coca-Cola beverages across its U.S. restaurants is drawing attention, with traders viewing the deal as a competitive win for KO and debating whether the rally can continue. The conversation also highlights KOs defensive relative strength amid tech weakness, alongside concerns that the shares look extended.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

A sharp, volatile pullback has investors focused on whether CLS can hold support, with some traders buying the dip while others expect further declines. The selloff is being weighed against optimism about AI-infrastructure demand and an upcoming earnings report, though traders disagree on whether that optimism is already priced in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNEWTON, Mass., Oct. 1, 2026NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Sept. 1, 2026 NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PR Newswire NEWTON, Mass...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 20, 2026 NEW YORK, Aug. 20, 2026...

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission PR Newswire NEWTON, Mass., Aug. 13, 2026...

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 PR Newswire NEWTON, Mass., Aug. 10, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --NEWTON, Mass., Aug. 10...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026...

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Why Is KPTI Stock Down 69% After-Hours Today?

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer.</li><li>Company officials said they were disappointed by the unexpected outcome and will cut planned spending on the endometrial cancer program.</li><li>Chief Executive Richard Paulson said that the company remains focused on its myelofibrosis program.</li></ul> Shares of Karyopharm Therapeutics (KPTI) fell 69% in after-hours trading on Thursday after the biotech company reported that its drug selinexor failed to delay disease progression meaningfully in endometrial cancer in a late-stage clinical trial. &nbsp;<h2 class="st-heading-2">What Did The Trial Show?</h2>The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer. It did not show a statistically significant delay in disease progression. A trend toward longer progression-free survival was seen in a key patient group—roughly 13 months for those on selinexor versus about 7.5 months on placebo—but the difference did not reach the required threshold for success, the company said.Safety results matched the drug’s known profile, the company said, with no new concerns identified. Company officials said they were disappointed by the unexpected outcome and will cut planned spending on the endometrial cancer program while completing a full data review for presentation at a future medical meeting. They plan to keep following patients for longer-term survival results.<h2 class="st-heading-2">KPTI’s Steps Ahead</h2>“While the results we are announcing today fell short of our expectations, they do not diminish our confidence in the broader potential of selinexor,” said Chief Executive Richard Paulson. He added that the company remains focused on its myelofibrosis program.In a separate announcement the same day, Karyopharm said it plans to submit an application to the U.S. Food and Drug Administration in August seeking accelerated approval for selinexor combined with ruxolitinib as a treatment for myelofibrosis. If cleared, the combination could become the first approved dual therapy for the rare blood cancer. The company intends to request priority review, which could lead to a decision about six months after submission.Paulson called the planned filing a potentially transformative step for patients and for the company.Selinexor, sold as Xpovio, is already FDA-approved for treating multiple myeloma in certain adult patients. Karyopharm reported U.S. XPOVIO (selinexor) net product revenue of $114.9 million for the full year 2025, accounting for a major portion of the company’s overall revenue. &nbsp;However, earlier this year, the FDA withdrew selinexor’s accelerated approval for a type of lymphoma after Karyopharm did not complete a required confirmatory trial, reducing its total addressable market.<h2 class="st-heading-2">How Did KPTI Retail Traders React?</h2>On Stocktwits, retail sentiment around KPTI rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume stayed at normal levels.A Stocktwits user said that partnerships may help the company continue its pipeline efforts.<stembedurl>https://www.stocktwits.com/joe77w/message/660525957</stembedurl>Another dismissed the after-hours selloff, noting that the company already has approvals in place and a remaining pipeline.<stembedurl>https://www.stocktwits.com/Tea_n_crumpet_enjoyer/message/660523869</stembedurl><a href="https://stocktwits.com/symbol/KPTI">KPTI stock</a> has fallen 5% year-to-date.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/phat-stock-clocks-worst-day-in-over-1-5-years-what-sparked-the-selloff/cZN5iRSRJ2B">PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer.Company officials said they were disappointed by the unexpected outcome and will cut planned spen

Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal. 


Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$0.346
Prev Close	$0.3901
Open	$0.40
Dividend Yield	0.00%
50-Day Moving Average	$1.47
Beta	0.87
Avg. Volume	1.43M
PE Ratio	-0.03

52-Week High	$10.99
52-Week Low	$0.31
Market Capitalization	$8.85M
EPS (Annual)	-$17.93
Price to Book	-0.02
Revenue Per Employee	$640,644.74

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPTI Fundamentals